secwatch.observer — SEC 8-K summary
======================================

Issuer:     BiomX Inc. (PHGE)
CIK:        0001739174
Form:       8-K
Filed at:   2025-05-15T23:59:59+00:00
Accession:  0001213900-25-043699
Event type: earnings
Sentiment:  neutral
Materiality: 0.55
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

BiomX Q1 net loss $7.7M; cash $21.2M; BX004 Phase 2b topline Q1 2026
--------------------------------------------------------------------

- Net loss of $7.7M for Q1 2025, compared to $17.3M in Q1 2024; R&D expenses rose to $5.3M from $4.1M.
- Cash and restricted cash $21.2M as of March 31, 2025; expects runway into Q1 2026.
- Positive Phase 2 results for BX211 in diabetic foot osteomyelitis announced March 2025; planning Phase 2/3 trial pending FDA feedback.
- BX004 Phase 2b in cystic fibrosis on track to report topline results in Q1 2026; regulatory discussions expected H2 2025.
- Shareholders approved exercise of warrants from $12M February 2025 financings in April 2025, extending operational runway.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1739174/000121390025043699/0001213900-25-043699-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1739174/000121390025043699/ea0242319-8k_biomxinc.htm
  HTML page:      https://secwatch.observer/filing/0001213900-25-043699

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer